Efficacy of avelumab plus axitinib for advanced renal cell carcinoma as late-line therapy: A case report.

Uekawa, Ayano; Kurahashi, Ryoma; Motoshima, Takanobu; Murakami, Yoji; Yatsuda, Junji; Kamba, Tomomi

Uekawa, Ayano; Kurahashi, Ryoma; Motoshima, Takanobu; Murakami, Yoji; Yatsuda, Junji; Kamba, Tomomi.

Afiliação

Uekawa A; Department of Urology, Faculty of Life Sciences, Kumamoto University, 1-1-1 Honjo, Chuo-ku, Kumamoto, 860-8556, Japan.
Kurahashi R; Department of Urology, Faculty of Life Sciences, Kumamoto University, 1-1-1 Honjo, Chuo-ku, Kumamoto, 860-8556, Japan.
Motoshima T; Department of Urology, Faculty of Life Sciences, Kumamoto University, 1-1-1 Honjo, Chuo-ku, Kumamoto, 860-8556, Japan.
Murakami Y; Department of Urology, Faculty of Life Sciences, Kumamoto University, 1-1-1 Honjo, Chuo-ku, Kumamoto, 860-8556, Japan.
Yatsuda J; Department of Urology, Faculty of Life Sciences, Kumamoto University, 1-1-1 Honjo, Chuo-ku, Kumamoto, 860-8556, Japan.
Kamba T; Department of Urology, Faculty of Life Sciences, Kumamoto University, 1-1-1 Honjo, Chuo-ku, Kumamoto, 860-8556, Japan.

Urol Case Rep ; 45: 102198, 2022 Nov.

Article em En | MEDLINE | ID: mdl-36072283

Palavras-chave

Avelumab plus axitinib; Combination therapy; IO-TKI combo; Late line; Metastatic renal cell carcinoma

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Urol Case Rep Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Japão

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google